Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Sumitomo Resolved to Revive Business, Optimize Japan Organization: New CEO
Sumitomo Pharma needs to restructure its domestic operations now that it has more or less set the scene for the turnaround of its North American business, Toru Kimura, who was appointed president and CEO on June 25, said to Jiho…
To read the full story
Related Article
- Sumitomo Ups FY2025 Forecast on North America-Driven Profit Growth
November 4, 2025
- Sumitomo Pharma Rejoins PhRMA amid US Tariff Concerns, Posts H1 Forecasts
August 1, 2025
- Sumitomo Pharma Logs 1st Operating Profit in 3 Years in FY2024
May 14, 2025
- Sumitomo Ups FY2024 Earnings Outlook, Now Expects Black Ink
February 3, 2025
- Sumitomo’s FY2024 1H Results Meet Initial Plan amid Restructuring
October 31, 2024
- Sumitomo Sales Surge 18% in April-September on 3 Key Brands
October 31, 2024
- As Latuda Sales Evaporate, Sumitomo Shakes Up Top Brass for Turnaround
May 15, 2024
- Sumitomo Pharma Replaces CEO amid Dismal Earnings
May 14, 2024
- Sumitomo Sets Out for Reconstruction, Further Cost Cuts in FY2024
May 2, 2024
- Sumitomo’s FY2023 Operating Loss Outlook Swells to 354.9 Billion Yen
May 2, 2024
BUSINESS
- China First to Approve Takeda’s Oveporexton for Narcolepsy
July 24, 2026
- FRONTEO Expects First US User of KIBIT AI Engine This Year: CEO
July 24, 2026
- Torii to Transfer Locoid MA in Japan to Cheplapharm
July 24, 2026
- Japan Vaccine Market Seen Flat in FY2026; Efluelda Delay Clouds Outlook
July 24, 2026
- Nipro Recalls Febuxostat after Finding Expired API Use at Another Plant
July 23, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…